Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.

View in: PubMed

subject areas

Aged
Carcinoma, Hepatocellular
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Liver Neoplasms
Male
Middle Aged
Neoplasm Proteins
Neoplasm Staging
Protein Kinase Inhibitors
Quinazolines
Vascular Endothelial Growth Factor Receptor-1

authors with profiles

Jeffrey A Meyerhardt, M.D.
Jeffrey G. Supko, Ph.D.
Rakesh K. Jain, Ph.D.
Nadine Jackson McCleary, M.D.
Dushyant V. Sahani, M.D.
Dan Gabriel Duda, Ph.D., D.M.D.
Andrew Xiuxuan Zhu, Ph.D., M.D.
Lawrence Scott Blaszkowsky, M.D.
David P. Ryan, M.D.
Thomas Adam Abrams, M.D.